AssetMark Inc’s Lexicon Pharmaceuticals LXRX Stock Holding History

AssetMark Inc’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-10,000	Closed	-$15.3K	–	2040
2023 Q4	$15.3K	Buy	+10,000	New	+$11.9K	﹤0.01%	1323

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Pinnacle Associates New York $9.16B AUM 63.5% 1-Year Est. Return

AssetMark Inc's LXRX Position: Q1 2024 in Review

AssetMark Inc sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2024, closing a stake of 10,000 shares — an estimated $15.3K sold.

AssetMark Inc first reported a position in LXRX in Q4 2023 and held it in 1 quarter. The position peaked at $15.3K in Q4 2023. 119 funds tracked by Wall St. Rank hold LXRX as of Q1 2024.

AssetMark Inc reported no remaining Lexicon Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
AssetMark Inc sold 10,000 Lexicon Pharmaceuticals shares in Q1 2024, an estimated $15.3K.
AssetMark Inc first reported a position in Lexicon Pharmaceuticals in Q4 2023 and held it in 1 quarter.
AssetMark Inc's Lexicon Pharmaceuticals position peaked at $15.3K in Q4 2023.
119 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2024.

Based on AssetMark Inc's 13F filing for Q1 2024, filed 7 May 2024.